Every reason behind the verdict rather than the headline one — which of your certifications match, how much runway is left, whether the work is your size, and what we would need to know to sharpen it.
Written against this notice and what you have told us about your company. Anything we do not know is marked [NEEDS INPUT] in the draft rather than guessed at — read it before you send it.
Start a free trial to draft these. Nothing is sent to an agency on your behalf, ever — you get a document to review, edit and submit yourself.
Sources Sought response
A complete draft response — capability statement, relevant past performance, business size and socioeconomic status, and answers to the agency's specific questions.
Questions to submit
Genuine ambiguities and requirements that disadvantage a smaller bidder, drafted as questions you can submit before the Q&A deadline.
Past performance write-ups
Which of your prior awards best match this requirement, and draft write-ups in the format the agency asked for.
Solicitation details
Solicitation number
S-195396
Notice type
Special Notice
NAICS
325412
Product service code
6505
Set-aside
No Set aside used
Posted
2026-06-04
Response deadline
Dec 4, 2026, 12:00 AM UTC
Place of performance
Los Alamos, NM
Contracting contact
licensing@lanl.gov
Market intelligence
Account requiredWho wins this work, and what it pays
Comparable awards under NAICS 325412 at this agency — the incumbent, what they were paid, when their period of performance ends, and the real pricing distribution rather than the headline number. From public federal award records.
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations. The Opportunity: Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable treatment modalities. By enabling more precise control over where and how therapeutic gases are delivered, the platform has the potential to unlock new product categories, enhance combination treatment strategies and accelerate translation of gas-based therapeutics into high-value clinical markets. How it Works: The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies. Key Advantages: Localized delivery: Targets therapeutic gases to the intended site while minimizing systemic exposure. Controlled release: Designed for sustained, tunable dosing under physiological conditions. Improved safety margin: Aims to separate therapeutic effect from toxicity risk. Platform versatility: Applicable across oncology, cardiovascular, neurological and regenerative indications. Development optimization: Supported by predictive modeling to guide dose and design decisions. Partnership-ready architecture: Suitable for integration with drug-device combinations and existing treatment modalities. Market Applications: Oncology Therapeutics Industry Cardiovascular and Vascular Medicine Industry Neurology and Neurodegenerative Disease Sector Regenerative Medicine and Tissue Engineering Industry Medical Device and Drug-Device Combination Companies Biotechnology and Specialty Pharma Companies Computational Drug Development and Modeling Firms Development Status: TRL 2 US patent pending LA-UR-26-22810 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology m.lanl.gov/tech-search
Contact
Point of contact
Caleb Ledgerwood
Role
not stated on this notice — SAM publishes a role for only about 5% of them, so this may be a contract specialist rather than the contracting officer
Email
licensing@lanl.gov
Secondary
licensing@lanl.gov
Submit questions
Ambiguities and requirements worth clarifying, written as questions you can send before the deadline.
Opens in your own mail client, addressed and with a subject line — you write the message. GovSprint never sends anything on your behalf.
Emails open in your mail client and are sent from your address, so the reply comes back to you and the exchange stays yours. Confirm the correct channel and any question deadline on the notice before sending — many solicitations require questions in a specific way.
